前列腺癌根治术后高危特征患者前列腺床立体定向放疗的II期干预性临床试验结果
本II期前瞻性试验评估前列腺癌根治术后高危特征患者接受前列腺床SBRT的安全性和疗效,49例患者分辅助、挽救和寡转移三组,中位随访60个月,5年无失败生存率60.9%,早期挽救患者5年FFF为74.7%,≥2级毒性仅4.1%,SBRT可行且毒性低,早期挽救结局与常规分割术后放疗历史结果相当。
要点
- 前列腺床SBRT 30-32 Gy/5次隔日照射,≥2级毒性仅4.1%。
- 全组5年无失败生存率60.9%,总生存率95.5%。
- 早期挽救(PSA 0.2-<0.5 ng/mL)5年FFF达74.7%。
核心结论
- 前列腺床SBRT可行,长期随访治疗相关毒性发生率低。
- 尤其早期挽救治疗患者的无失败结局有前景,与常规分割术后放疗历史结果相当。
研究设计与样本
- II期前瞻性干预性临床试验,2018年5月至2020年5月入组49例前列腺癌根治术后高危特征患者。
- 按临床情景分三组:I组辅助SBRT(PSA<0.2 ng/mL伴不良特征)、II组挽救SBRT(PSA≥0.2且<2.0 ng/mL)、III组寡转移(≤5处)。
- 所有患者接受前列腺床SBRT总剂量30-32 Gy分5次隔日照射。
- 挽救组和寡转移组分别接受6个月和18个月雄激素剥夺治疗(ADT)。
- 主要终点为无失败生存(FFF),定义为PSA<0.5 ng/mL且无临床进展或重启ADT。
主要发现
- 中位随访60个月;高危特征包括包膜外侵犯49%、精囊侵犯10%、切缘阳性55%、Gleason评分8-10分22%,手术时无淋巴结受累。
- 入组时中位PSA为0.35 ng/mL(I组0.11、II组0.42、III组0.39)。
- 仅2例(4.1%)发生≥2级毒性(I组1例血尿、II组1例直肠出血),III组无显著不良事件。
- 5年FFF率为60.9%(95%CI 48.3%-76.9%);早期挽救患者5年FFF为74.7%(95%CI 62.7%-89.0%;HR 0.33,95%CI 0.04-3.17)。
- 全组总生存率为95.5%(95%CI 89.7%-100%)。
关键数值与推荐
- SBRT剂量30-32 Gy分5次隔日给予。
- 挽救组ADT 6个月,寡转移组ADT 18个月。
- FFF定义:PSA<0.5 ng/mL且无临床进展或重启ADT。
- 早期挽救定义为PSA 0.2至<0.5 ng/mL。
- 毒性按CTCAE v5.0分级。
临床怎么用
- 前列腺床SBRT可作为根治术后高危特征患者的可行治疗选择,毒性低。
- 早期挽救治疗(PSA 0.2-<0.5 ng/mL)患者可能获得更优无失败结局。
- PSA≥0.2 ng/mL患者应行C11 PET分期,生化失败后应行PSMA PET再分期。
局限性
- II期单臂研究,样本量49例,无随机对照。
- 早期挽救亚组HR的95%CI宽(0.04-3.17),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study reports the safety and efficacy outcomes of a phase II prospective trial evaluating stereotactic body radiation therapy (SBRT) to the prostate bed in patients with high-risk features following radical prostatectomy. METHODS AND MATERIALS: Between May 2018 and May 2020, 49 patients were enrolled and stratified into 3 groups based on clinical context: group I (adjuvant SBRT, PSA < 0.2 ng/mL with adverse features such as positive margins, seminal vesicle invasion (SVI), or extraprostatic extension), group II (salvage SBRT, PSA ≥ 0.2 and <2.0 ng/mL), and group III (oligometastatic disease, ≤5 sites). Patients with PSA ≥ 0.2 ng/mL underwent staging with C11 positron emission tomography (PET); those with biochemical failure following treatment were restaged with PSMA PET. All patients received SBRT to the prostate bed to a total dose of 30 to 32 Gy in 5 fractions administered every other day. Patients in the salvage and oligometastatic groups received 6 and 18 months of androgen deprivation therapy (ADT), respectively. The primary endpoint was freedom from failure (FFF), defined as a PSA < 0.5 ng/mL without clinical progression or reinitiation of ADT. Secondary endpoints included FFF with a PSA < 0.2 ng/mL, toxicity rates (graded per CTCAE v5.0), clinical failure, and FFF in early salvage patients (PSA 0.2 to <0.5 ng/mL). RESULTS: The median follow-up was 60 months. High-risk features included extraprostatic extension in 49%, SVI in 10%, positive margins in 55%, and Gleason score 8 to 10 in 22%; no patients had nodal involvement at surgery. The median PSA at enrollment was 0.35 ng/mL (0.11 for group I, 0.42 for group II, and 0.39 for group III). SBRT was well tolerated, with only 2 (4.1%) cases of grade ≥2 toxicity (one case of hematuria in group I and one of rectal bleeding in group II); no significant adverse events were observed in group III. Five-year FFF rate was 60.9% (95% confidence interval [CI], 48.3%-76.9%). Improved FFF was observed in early salvage patients, at 5 years it was 74.7% (95% CI, 62.7%-89.0%); hazard ratio [HR], 0.33; 95% CI, 0.04-3.17). Overall survival was 95.5% (95% CI, 89.7%-100%) for all cases. CONCLUSIONS: SBRT to the prostate bed was feasible and associated with a low incidence of treatment-related toxicity over long-term follow-up. The observed FFF outcomes-particularly among patients treated in the early-salvage setting-were promising and appear comparable with historical results from conventionally fractionated postprostatectomy radiation therapy.
引用
- Vargas CE, Voss MM, Dodoo C, et al. Outcomes of a Phase II Interventional Clinical Trial of Prostate Bed Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features Following Radical Prostatectomy. Int J Radiat Oncol Biol Phys. 2026. PMID: 41713512. doi:10.1016/j.ijrobp.2026.02.194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。